Home
Covid-19
Tools
Introduction to the Tools
Model Government Use Licences
Model Uses of Paragraph 7 or “LDC Waiver”
Special Compulsory Licences for Export of Medicines
Options for Regional Economic Communities
Voluntary Licences
TRIPS Flexibilities Database
Resources
Briefs & Briefing Documents
Publications
Tools
Useful Links
All Resources
Blog
About
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Password recovery
Recover your password
your email
Search
Medicines Law & Policy
Research and resources on intellectual property and health
Home
Covid-19
Tools
Introduction to the Tools
Model Government Use Licences
Model Uses of Paragraph 7 or “LDC Waiver”
Special Compulsory Licences for Export of Medicines
Options for Regional Economic Communities
Voluntary Licences
TRIPS Flexibilities Database
Resources
Briefs & Briefing Documents
Publications
Tools
Useful Links
All Resources
Blog
About
Tag: Gilead
Price, profit and the Covid-19 health technology pool: The example of...
Christopher Garrison
-
May 28, 2020
CJEU Ruling on Truvada recalls ‘evergreening’ goes against public health interests
Pascale Boulet
-
September 10, 2018
The Power of TRIPS Flexibilities in Medicines Procurement
Ellen 't Hoen
-
April 9, 2018
Gilead’s sofosbuvir patent in India – options for global access to...
Ellen 't Hoen
-
May 26, 2016
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Ok
This work is licensed under Creative Commons.